Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Oral isotretinoin: ensuring safe use while not limiting access to those who need it

Jerry K.L. Tan and Neil Shear
CMAJ April 03, 2017 189 (13) E510; DOI: https://doi.org/10.1503/cmaj.732920
Jerry K.L. Tan
Dermatologist, Faculty of Medicine, Western University, London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Shear
Professor, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

In a Canadian study published in CMAJ, the finding of 3.1 pregnancies per 1000 female isotretinoin users between 1996–2011 is cause for concern for all prescribers of this medication.1 The authors proffer potential reasons for inadvertent fetal exposure to oral isotretinoin, including marketing of generic versions that may have fewer consumer educational resources than the original, online availability without prescription or appropriate risk information, and increased use for milder forms of acne.1 The latter requires response from a dermatologic perspective.

The designation of clinical severity is problematic. Acne severity is multidimensional, comprising primary acne lesions (type, lesion intensity, extent and distribution), scarring and psychosocial impact. However, acne guidelines typically refer to clinician assessments based on a static evaluation of primary acne lesions.2 Furthermore, acne is a chronic condition with a potential for adverse psychosocial consequences — an impact not directly correlated with clinical severity as judged by clinicians.3 Psychosocial impact may be severe despite acne being mild or moderate on clinical examination, while severe acne increases the risk of attempted suicide. In patients requiring oral isotretinoin for severe acne, increased suicide risk was observed even before institution of this medication.4

Furthermore, post-acne scarring is not included as a dimension in current acne severity scales. Scarring has been observed in those clinically assessed with mild-to-moderate as well as severe acne. This reflects fluctuation in severity and intense inflammation leading to dermal damage. Post-acne scarring is a marker for more severe acne with its own psychosocial effects and treatment consequences, typically invasive and costly.

Although oral isotretinoin has been the standard of care for severe acne,2 the management of moderate acne has evolved with increasing recognition of the public health consequences of prolonged antibiotic use.

Current guidelines recommend limiting the use of oral antibiotics to three to four months to mitigate this risk.5 These agents are unlikely to lead to remission and their discontinuation generally leads to acne recurrence, and consequently, the need for an alternative systemic option such as oral isotretinoin. The latter remains the sole agent with the potential for inducing remission in acne.6

Pregnancy prevention programs have developed in parallel with the availability of oral isotretinoin in the United States and Canada over the past three decades. In the US, these have evolved through warnings on labels; addition of red label stickers to pharmacies; addition of “avoid pregnancy” icons; patient consent forms; pregnancy testing before start of treatment; selection of two forms of birth control (Pregnancy Prevention Program [PPP], 1988); two pregnancy tests before starting treatment and pharmacist provision of a medication guide with prescriptions; dispensing limited to 30-day supply with no refills (SMART, 2001); monthly pregnancy tests; a registration database for patients, prescribers, pharmacists and wholesalers; qualifying questions for patients and monthly identification of contraceptive methods by patients and doctors (iPLEDGE, 2006).7

Despite these increasingly stringent pregnancy risk-management approaches, no significant reduction in pregnancies has been shown with SMART8 or iPLEDGE.9 A consequence of each, however, has been a sequential reduction in the number of isotretinoin treatment courses and the number of patients treated, with females being disproportionately affected. In Canada, the current program is similar to PPP, but with the addition of two pregnancy tests before starting treatment and monthly pregnancy tests, including one month after discontinuation.

The conclusion stated by the authors, that medical practitioners and female patients must be reminded of fetal risks of this medication — including adherence to pregnancy prevention program measures1 — is well founded and timely. Additional considerations are the multidimensional nature of acne severity and the potential for morbidity and mortality in a subgroup of patients. The ongoing challenge with oral isotretinoin in Canada is safe and appropriate use while not limiting access to those who need it.

Footnotes

  • Competing interests: Dr. Jerry Tan has been an advisor, consultant and/or speaker for Cipher and Roche. Dr. Neil Shear has been an advisor, consultant and/or speaker for Cipher.

References

  1. ↵
    1. Henry D,
    2. Dormuth C,
    3. Winquist B,
    4. et al
    .; CNODES (Canadian Network for Observational Drug Effect Studies) Investigators. Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. CMAJ 2016;188:723–30.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Asai Y,
    2. Baibergenova A,
    3. Dutil M,
    4. et al
    . Management of acne: Canadian clinical practice guideline. CMAJ 2016;188:118–26.
    OpenUrlFREE Full Text
  3. ↵
    1. Tan JK,
    2. Li Y,
    3. Fung K,
    4. et al
    . Divergence of demographic factors associated with clinical severity compared with quality of life impact in acne. J Cutan Med Surg 2008;12:235–42.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Sundström A,
    2. Alfredsson L,
    3. Sjölin-Forsberg G,
    4. et al
    . Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010;341:c5812.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Zaenglein AL,
    2. Pathy AL,
    3. Schlosser BJ,
    4. et al
    . Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:945–73.e33.
    OpenUrl
  6. ↵
    1. Blasiak RC,
    2. Stamey CR,
    3. Burkhart CN,
    4. et al
    . High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol 2013; 149:1392–8.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Abroms L,
    2. Maibach E,
    3. Lyon-Daniel K,
    4. et al
    . What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006; 3:e483.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Brinker A,
    2. Kornegay C,
    3. Nourjah P
    . Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Arch Dermatol 2005;141:563–9.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Shin J,
    2. Cheetham TC,
    3. Wong L,
    4. et al
    . The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. J Am Acad Dermatol 2011;65:1117–25.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (13)
CMAJ
Vol. 189, Issue 13
3 Apr 2017
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Oral isotretinoin: ensuring safe use while not limiting access to those who need it
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Oral isotretinoin: ensuring safe use while not limiting access to those who need it
Jerry K.L. Tan, Neil Shear
CMAJ Apr 2017, 189 (13) E510; DOI: 10.1503/cmaj.732920

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Oral isotretinoin: ensuring safe use while not limiting access to those who need it
Jerry K.L. Tan, Neil Shear
CMAJ Apr 2017, 189 (13) E510; DOI: 10.1503/cmaj.732920
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Building research infrastructure across a health service
  • A safe return to sport and the right to play during COVID-19
  • Simple-language tool to guide patients in recovery after prolonged treatment in the intensive care unit
Show more Letters

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire